Injection drug use and HIV. past and future considerations for HIV prevention and interventions

HIV Prevention

Volumn , Issue , 2009, Pages 305-339

  Fuller, Crystal M ^a   Ford, Chandra ^a   Rudolph, Abby ^b  

^a Mailman School of Public Health   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78549252181     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374235-3.00012-1     Document Type: Chapter

References (156)

1. Absalon J., Fuller C.M., Ompad D., et al. Gender differences in sexual behaviors, sexual partnerships, and HIV among drug users in New York City. AIDS Behav. 2006, 10(6):707-715.
2. Ahern J., Stuber J., Galea S. Stigma, discrimination and the health of illicit drug users. Drug Alcohol Depend. 2007, 88(2-3):188-196.
3. Airhihenbuwa C.O., DiClemente R.J., Wingood G.M., Lowe A. HIV/AIDS education and prevention among African-Americans: a focus on culture. AIDS Educ. Prev. 1992, 4:267-276.
4. Anderson W. The New York Needle Trial: the politics of public health in the age of AIDS. Am. J. Public Health 1991, 81:1506-1517.
5. Anthony J.C., Vlahov D., Nelson K.E., et al. New evidence on intravenous cocaine use and the risk of infection with human immunodeficiency virus type 1. Am. J. Epidemiol. 1991, 134:1175-1189.
6. Astemborski J., Vlahov D., Warren D., et al. The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users. Am. J. Public Health 1994, 84:382-387.
7. Ball A.L. Averting a global epidemic. Addiction 1996, 91:1095-1098.
8. Ball A.L., Rana S., Dehne K.L. HIV prevention among injecting drug users, responses in developing and transitional countries. Public Health Rep. 1998, 113(Suppl. 1):170-181.
9. Baral S., Sifakis F., Cleghorn F., Beyrer C. Elevated risk for HIV infection among men who have sex with men in low- and middle-income countries 2000-2006: a systematic review. PLoS Med. 2007, 4:1901-1911.
10. Battjes R.J., Pickens R.W., Amsel Z. HIV infection and AIDS risk behaviors among intravenous drug users entering methadone treatment in selected US cities. J. Acquir. Immune Defic. Syndr. 1991, 4:1148-1154.
11. Bell A.V., Ompad D., Sherman S.G. Sexual and drug risk behaviors among women who have sex with women. Am. J. Public Health 2006, 96:1066-1072.
12. Berger M.T. Workable Sisterhood: The Political Journey of Stigmatized Women with HIV/AIDS 2004, . Princeton, NJ: Princeton University Press.
13. Blankenship K.M., Smoyer A.B., Bray S.J., Mattocks K. Black-white disparities in HIV/AIDS: the role of drug policy and the corrections system. J. Health Care Poor Underserved 2005, 16(Suppl. B):140-156.
14. Bluthenthal R.N., Watters J.K. Multimethod research from targeted sampling to HIV environments. NIDA Research Monographs 1995, 157:212-230.
15. Bluthenthal R.N., Kral A.H., Lorvick J., Watters J.K. Impact of law enforcement on syringe exchange programs, a look at Oakland and San Francisco. Med. Anthropol. 1997, 18:61-83.
16. Boardman J.D., Finch B.K., Ellison C.G., et al. Neighborhood disadvantage, stress, and drug use among adults. J. Health Social Behav. 2001, 42:151-165.
17. Bobrova N., Rhodes T., Powers R., et al. Barriers to accessing drug treatment in Russia, a qualitative study among injecting drug users in two cities. Drug Alcohol Depend. 2006, 82(Suppl. 1):S57-S63.
18. Booth R.E., Watters J.K., Chitwood D.D. HIV risk-related sex behaviors among injection drug users, crack smokers, and injection drug users who smoke crack. Am. J. Public Health 1993, 83:1144-1148.
19. Broadhead R.S. Social construction of bleach in combating AIDS among injection drug users. J. Drug Issues 1991, 21:713-737.
20. Brooner R.K., Bigelow G.E., Strain E., Schmidt C.W. Intravenous drug abusers with antisocial personality disorder: increased HIV risk behavior. Drug Alcohol Depend. 1990, 26:39-44.
21. Burris S., Welsh J., Mitzi N.G., et al. State syringe and drug possession laws potentially influencing safe syringe disposal by injection drug users. J. Am. Pharm. Assoc. 2002, 42:S94-S98.
22. Calsyn D.A., Saxon A.J., Freeman G., Wittaker S. Needle-use practicesamong intravenous drug users in an area where needle purchase is legal. AIDS 1991, 5:187-193.
23. Carceres, W., Blaney, S., Lewis, E. et al. (2006). Pharmacy syringe access program for injection drug users in New York City: policy recommendation for targeted advertisement to increase sterile syringe access through pharmacies. Annual Meeting of the American Public Health Association, Boston, MA.
24. CDC (2001). Women, injection drug use and the criminal justice system. Available at (accessed 02-29-08). http://www.cdc.gov/idu/facts/cj-women.pdf.
25. Drug-associated HIV Transmission Continues in the United States. 2002, CDC, Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention.
26. Advancing HIV prevention, new strategies for a changing epidemic - United States. Morbid. Mortal. Wkly Rep. 2003, 52:329-332. CDC.
27. CDC (2005). HIV prevalence among selected populations: high-risk populations. Available at (accessed 06-06-2008). http://www.cdc.gov/hiv/topics/testing/resources/reports/hiv_prevalence/h igh-risk.htm#figure11.
28. CDC (2004). HIV/AIDS Surviellance Report. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, 16(21), Table 11.
29. Racial/ethnic disparities in diagnoses of HIV/AIDS - 33 states, 2001-2005. Morbid. Mortal. Wkly Rep. 2007, 56:189-193. CDC.
30. Chan K.Y., Yang Y., Zhang K., Reidpath D.D. Disentangling the stigma of HIV/AIDS from the stigmas of drugs use, commercial sex and commercial blood donation - a factorial survey of medical students in China. BMC Public Health 2007, 7:280.
31. Chatterjee A., Uprety L., Chapagain M., Kafle K. Drug abuse in Nepal, a rapid assessment study. Bull. Narcotics 1996, 48(1-2):11-33.
32. Compton W.M., Cottler L.B. The effects of psychiatric comorbidity on response to an HIV prevention intervention. Drug Alcohol Depend. 2000, 58:247-257.
33. Compton W.M., Cottler L.B., Ben-Abdallah A., et al. The effects of psychiatric comorbidity on response to an HIV prevention intervention. Drug Alcohol Depend. 2000, 58:247-257.
34. Cooper H., Friedman S.R., Tempalski B., et al. Racial/ethnic disparities in injection drug use in large US metropolitan areas. Ann. Epidemiol. 2005, 15:326-334.
35. Copenhaver M., Johnson B.T., Lee I.E., et al. Behavioral HIV risk reduction among people who inject drugs: meta-analytic evidence of efficacy. J. Subst. Abuse 2006, 31:63-171.
36. Culbert H., Tu D., O'Brien D.P., et al. HIV treatment in a conflict setting, outcomes and experiences from Bukavu, Democratic Republic of the Congo. PLoS Med. 2007, 4:e129.
37. AIDS Prevention and Control Programme 1993. Sentinel Surveillance Data. 1993, Department of Health Union of Myanmar, Yango.
38. Des Jarlais, D. C., Marmor, M., Panone, D. et al. HIV incidence among injecting drug users in NYC syringe-exchange programmes. Lancet, 348, 987-91.
39. Des Jarlais D.C., Friedman S.R., Perlis T., et al. Risk behavior and HIV infection among new drug injectors in the era of AIDS in New York City. J. Acquir. Immune Defic. Syndr. 1999, 20:67-72.
40. Des Jarlais D.C., Marmor M., Paone D., et al. HIV incidence among injection drug users in New York City, 1992-1997, evidence for a declining epidemic. Am. J. Public Health 2000, 90:352-359.
41. Diaz T., Vlahov D., Greenberg B., et al. Sexual orientation and HIV infection prevalence among young Latino injection drug users in Harlem. J. Women's Health Gender-based Med. 2001, 10:371-380.
42. Doherty M.C., Garfein R.S., Monterroso E., et al. Correlates of HIV infection among young adult short-term injection drug users. AIDS 2000, 14:717-726.
43. Dorabjee, J., Samson, L. and Dyalchand, R. (1996). A community-based intervention for injecting drug users (IDUs) in New Delhi slums. Paper presented at the XIth International Conference on AIDS, 7-12 July, Vancouver, Canada.
44. Edlin B.R., Irwin K.L., Faruque S., et al. Intersecting epidemics - crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team. N. Engl. J. Med. 1994, 331:1422-1427.
45. El-Bassel N.L., Gilbert E., Wu G., et al. Relationship between drug abuse and intimate partner violence, a longitudinal study among women receiving methadone. Am. J. Public Health 2005, 95:465-470.
46. Evans J.L., Hahn J.A., Page-Shafer K., Lum P.J. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (The UFO Study). J. Urban Health 2003, 80:137-146.
47. Farrell M., Neeleman J., Gossop M., et al. Methadone provision in the European Union. Intl J. Drug Policy 1995, 6:168-172.
48. Farzadegan H., Hoover D.R., Astemborski J., et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998, 352:1510-1514.
49. Feldman H.W., Biernacki P. The ethnography of needle sharing among intravenous drug users and implications for public policies and intervention strategies. NIDA Res. Monogr. 1988, 80:28-39.
50. Fennema J.S., van Ameijden E.J., van den Hoek A., Coutinho R.A. Young and recent-onset injection drug users are at higher risk for HIV. Addiction 1997, 92:1457-1465.
51. Ford C.L., Miller W.C., Smurzynski M., Leone P.A. Key components of a theory-guided HIV prevention outreach model: pre-outreach preparation, community assessment, and a network of key informants. AIDS Educ. Prev. 2007, 19:173-186.
52. Friedman S.R., Jose B., Deren S., et al. Risk factors for human immunodeficiency virus seroconversion among out-of-treatment injectors in high and low seroprevalence cities. The National AISA Research Consortium. Am. J. Epidemiol. 1995, 142:864-874.
53. Friedman S.R., Ompad D.C., Maslow C., et al. HIV prevalence, risk behaviors, and high-risk sexual and injection networks among young women injectors who have sex with women. Am. J. Public Health 2003, 93:902-906.
54. Frye V., Latka M.H., Wu Y., et al. Intimate partner violence perpetration against main female partners among HIV-positive male injection drug users. J. Acquir. Immune Defic. Syndr. 2007, 46(Suppl. 2):S101-S109.
55. Fuller C.M., Vlahov D., Arria A.M., et al. Factors associated with adolescent initiation of injection drug use. Public Health Rep. 2001, 116(Suppl. 1):136-145.
56. Fuller, C. M., Ahern, J., Vadnai, L. et al. Impact of increased syringe access, preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York. J. Am. Pharm. Assoc., 42 (Suppl. 2), S77-82.
57. Fuller C.M., Vlahov D., Latkin C.A., et al. Social circumstances of initiation of injection drug use and early shooting gallery attendance, implications for HIV intervention among adolescent and young adult injection drug users. J. Acquir. Immune Defic. Syndr. 2003, 32:86-93.
58. Fuller C.M., Ompad D.C., Galea S., et al. Hepatitis C incidence - a comparison between injection and non-injection drug users in New York City. J. Urban Health 2004, 81:20-24.
59. Fuller C.M., Borrell L.N., Latkin C.A., et al. Effects of race, neighborhood, and social network on age at initiation of injection drug use. Am. J. Public Health 2005, 95:689-695.
60. Fuller C.M., Absalon J., Ompad D.C., et al. A comparison of HIV seropositive and seronegative young adult heroin- and cocaine-using men who have sex with men in New York City, 2000-2003. J. Urban Health 2005, 82(Suppl. 1):i51-i61.
61. Fullilove R.E., Fullilove M.T., Bowser B.P., Gross S.A. Risk of sexually transmitted disease among black adolescent crack users in Oakland and San Francisco, California. J. Am. Med. Assoc. 1990, 263:851-855.
62. Galea S., Ahern J., Valhov C. Contextual determinants of drug use risk behavior: a theoretic framework. J. Urban Health 2003, 80(Suppl. 3):iii50-iii58.
63. Garfein R.S., Vlahov D., Galai N., et al. Viral infections in short-term injection drug users, the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am. J. Public Health 1996, 86:655-661.
64. Godette D.C., Headen S., Ford C. Windows of opportunity, fundamental concepts for understanding alcohol-related disparities experienced by young Blacks in the United States. Prevent. Sci. 2006, 7:377-387.
65. Goldbaum G., Perdue T., Wolitski R., et al. Differences in risk behavior and sources of AIDS information among gay, bisexual, and straight-identified men who have sex with men. AIDS Behav. 1998, 2:13-21.
66. Gordon C.M., Forsyth A.D., Stall R., Cheever L.W. Prevention interventions with persons living with HIV/AIDS, state of the science and future directions. AIDS Educ. Prev. 2005, 17:6-20.
67. Gostin L.O., Lazzarini Z. Prevention of HIV/AIDS among injection drug users: the theory and science of public health and criminal justice approaches to disease prevention. Emory Law J. 1997, 46:587-696.
68. Groseclose S.L., Weinstein B., Jones T.S., et al. Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officers - Connecticut, 1992-1993. J. Acquir. Immune Defic. Syndr. 1995, 10:71-72.
69. Guenther-Grey C., Noroian D., Foneska J., Higgins D. Developing community networks to deliver HIV prevention interventions. Public Health Rep. 1996, 111(Suppl. 1):41-49.
70. Gyarmathy V.A., Neaigus A. The relationship of sexual dyad and personal network characteristics and individual attributes to unprotected sex among young injecting drug users. AIDS Behav. 2007, (e-pub ahead of print).
71. Hamers F.F., Batter V., Downs A., et al. The HIV epidemic associated with injecting drug use in Europe, geographic and time trends. AIDS 1997, 11:1365-1374.
72. Hangzo C., Chatterjee A., Sarkar S., et al. Reaching out beyond the hills, HIV prevention among injecting drug users in Manipur, India. Addiction 1997, 92:813-820.
73. Hankins C.A., Friedman S.R., Zafar T., Strathdee S.A. Transmission and prevention of HIV and sexually transmitted infections in war settings: implications for current and future armed conflicts. AIDS 2002, 16:2245-2252.
74. Harawa N., Adimora A. Incarceration, African Americans and HIV: advancing a research agenda. J. Natl Med. Assoc. 2008, 100:57-62.
75. Hein, N. (1995) Drug Use and HIV Infection in Viet Nam. Report of the WHO Drug Injecting Project Planning Meeting, Phase II. Bangkok: WHO.
76. Henderson D.J. Drug abuse and incarcerated women. J. Subst. Abuse Treat. 1998, 15:579-587.
77. Holmberg S.D. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am. J. Public Health 1996, 86:642-654.
78. Ibanez G.E., Purcell D.W., Stall R., et al. Sexual risk, substance use, and psychological distress in HIV-positive gay and bisexual men who also inject drugs. AIDS 2005, 19(Suppl. 1):S49-S55.
79. Iguchi M.Y., Bux D.A., Kushner H., Victor L. Correlates of HIV risk among female sex partners of injecting drug users in a high-seroprevalence area. Eval. Prog. Plan. 2001, 24:175-185.
80. Preventing HIV Infection among Injecting Drug Users in High-risk Countries: An assessment of the Evidence. Washington, DC: 2007, Institute of Medicine of the National Academies, National Academy of Sciences.
81. Jose B., Friedman S.R., Neaigus A., et al. Collective organization of injecting drug users and the struggle against AIDS. AIDS, Drugs and Prevention: Perspectives on Individual and Community Action 1996, 216-233. Routledge, London. T. Rhodes, R. Hartnoll (Eds.).
82. Klein S.J., Guthrie S., Candelas A.R. Expanded syringe access demonstration program in New York State: an intervention to prevent HIV/AIDS transmission. J. Urban Health 2000, 77:762-777.
83. Koester S.K. The context of risk, ethnographic contributions to the study of drug use and HIV. NIDA Res. Monogr. 1994, 143:202-217.
84. Kottiri B.J., Friedman S.R., Neaigus A., et al. Risk networks and racial/ethnic differences in the prevalence of HIV infection among injection drug users. J. Acquir. Immune Defic. Syndr. 2002, 30:95-104.
85. Kral A.H., Bluthenthal R.N., Booth R.E., Watters J.K. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. Am. J. Public Health 1998, 88:108-113.
86. Krieger N., Williams D.R., Moss N.E. Measuring social class in US public health research: concepts, methodologies, and guidelines. Annu. Rev. Public Health 1997, 18:341-378.
87. Lamothe F., Bruneau J., Coates R., et al. Seroprevalence of and risk factors for HIV-1 infection in injection drug users in Montreal and Toronto, a collaborative study. Can. Med. Assoc. J. 1993, 149:945-951.
88. Lange W.R., Snyder F.R., Lozovsky D., et al. Geographic distribution of human immunodeficiency virus markers in parenteral drug abusers. Am. J. Public Health 1988, 78:443-446.
89. Latkin C.A. Outreach in natural settings, the use of peer leaders for HIV prevention among injecting drug users' networks. Public Health Rep. 1998, 113(Suppl. 1):151-159.
90. Latkin C.A., Knowlton A.R. Micro-social structural approaches to HIV prevention, a social ecological perspective. AIDS Care 2005, 17(Suppl. 1):S102-S113.
91. Latkin C.A., Mandell W., Oziemkowska M., et al. Using social network analysis to study patterns of drug use among urban drug users at high risk for HIV/AIDS. Drug Alcohol Depend. 1995, 38:1-9.
92. Latkin C.A., Forman V., Knowlton A., Sherman S. Norms, social networks, and HIV-related risk behaviors among urban disadvantaged drug users. Social Sci. Med. 2003, 56:465-476.
93. Lau J.T., Zhang J., Zhang L., et al. Comparing prevalence of condom use among 15,379 female sex workers injecting or not injecting drugs in China. Sex. Transm. Dis. 2007, 34:908-916.
94. Maas B., Fairbairn N., Thomas K., et al. Neighborhood and HIV infection among IDU: place of residence independently predicts HIV infection among a cohort of injection drug users. Health Place 2007, 13:432-439.
95. MacDonald M., Law M., Kaldor J., et al. Effectiveness of needle and syringe programmes for preventing HIV transmission. Intl J. Drug Policy 2003, 14:353-357.
96. Maharjan, S. H. and Singh, M. (1996). Street-based outreach program for injecting drug users. Paper presented at the XIth International Conference on AIDS, July 7-12, Vancouver, Canada, Abstract no. Mo.D.244.
97. Marks G., Burris S., Peterman T.A. Reducing sexual transmission of HIV from those who know they are infected, the need for personal and collective responsibility. AIDS 1999, 13:297-306.
98. Mays V.M., Cochran S.D., Barnes N.W. Race, race-based discrimination, and health outcomes among African Americans. Ann. Rev. Psychol. 2007, 58:201-225.
99. Miller N.S., Sheppard L.M., Colenda C.C., Magen J. Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. Acad. Med. 2001, 76:410-418.
100. National Institute on Drug Abuse (2000). The Science of Drug Abuse and Addiction. Advance Report, Community Epidemiology Work Group. Available at . http://www.drugabuse.gov/CEWG/AdvancedRep/6_20ADV/0600adv.html.
101. Principles of HIV Prevention in Drug-using Populations 2002, National Institute on Drug Abuse, . Bethesda, MD: National Institute on Drug Abuse, Department of Health and Human Development.
102. National Institute on Drug Abuse (2006). Research Report, HIV/AIDS. Rockville, MD: National Clearinghouse on Alcohol and Drug Information, US Department of Health and Human Services, National Institutes of Health.
103. National Task Force on HIV/AIDS and Injection Drug Use (2001). HIV/AIDS and Injection Drug Use: A National Action Plan. Available at (accessed 02-29-08). http://www.cfdp.ca/hivaids.html.
104. Ndetei, D.(2004). UNODC Study on the Linkages between Drug Use, Injecting Drug Use and HIV/AIDS in Kenya. Nairobi: University of Nairobi.
105. Neaigus A., Friedman S.R., Jose B., et al. High-risk personal networks and syringe sharing as risk factors for HIV infection among new drug injectors. J. Acquir. Immune Defic. Syndr. 1996, 11:499-509.
106. Needle R.H., Coyle S.L., Norman J., et al. HIV prevention with drug-using populations-current status and future prospects, introduction and overview. Public Health Rep. 1998, 113(Suppl. 1):4-18.
107. Nelson K.E., Vlahov D., Solomon S., et al. Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, MD. Arch. Intern. Med. 1995, 155:1305-1311.
108. New York Academy of Medicine (2003). New York State Expanded Syringe Access Demonstration Program Evaluation. Evaluation Report to the Governor and the New York State Legislatures. New York, NY: New York Academy of Medicine.
109. New York City Department of Health and Mental Hygiene (2003). HIV Surveillance and Epidemiology Program. Quarterly Report. New York, NY: New York City Department of Health and Mental Hygiene.
110. New York State Department of Health, Bureau of HIV/AIDS Epidemiology (2000). AIDS Surveillance Quarterly Update for Cases Reported through March 2000. Albany, NY: New York State Department of Health, Bureau of HIV/AIDS Epidemiology.
111. New York State Department of Health, Bureau of HIV/AIDS Epidemiology (2007). New York State HIV/AIDS Surveillance Semiannual Report for Cases Diagnosed through December 2005. Available at . http://www.health.state.ny.us/diseases/aids/statistics/semiannual/2005/s urveillance_semiannual_report_2005-12.pdf.
112. Nicolosi A., Leite M.L., Molinari S., et al. Incidence and prevalence trends of HIV infection in intravenous drug users attending treatment centers in Milan and northern Italy, 1986-1990. J. Acquir. Immune Defic. Syndr. 1992, 5:365-373.
113. Ompad D., Fuller C.M. The urban environment, drug use, and health. Handbook of Urban Health 2005, 127-154. Springer, New York, NY. S. Galea, D. Vlahov (Eds.).
114. Pajares, F. (2002). Overview of social cognitive theory and of self efficacy. Available at (accessed 04-28-08). http://www.emory.edu/EDUCATION/mfp/eff.html.
115. Panchanadeswaran S., Johnson S., Sivaram C., et al. Intimate partner violence is as important as client violence in increasing street-based female sex workers' vulnerability to HIV in India. Intl J. Drug Policy 2008, 19:106-112.
116. Pokrovski, V. (1998). HIV Infections by Modes of Transmission in the Russian Federation. Report to UNAIDS. Russia: AIDS Center.
117. Pouget E.R., Deren S., Fuller C., et al. Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program. J. Acquir. Immune Defic. Syndr. 2005, 39:471-477.
118. Purcell D.W., Garfein R.S., Latka M.H., et al. Development, description, and acceptability of a small-group, behavioral intervention to prevent HIV and hepatitis C virus infections among young adult injection drug users. Drug Alcohol Depend. 2007, 91(Suppl. 1):S73-S80.
119. Qian H.-Z., Schumacher J.E., Chen H.T., Ruan Y. Injection drug use and HIV/AIDS in China, Review of current situation, prevention and policy implications. Harm Reduction J. 2006, 1:4.
120. Reynaud-Maurupt C., Carrieri N.P., Gastaud J.A., et al. Impact of drug maintenance treatment on injection practices among French HIV-infected IDUs. AIDS Care 2000, 12:461-470.
121. Rietmeijer C.A., Wolitski R.J., Fishbein M., et al. Sex hustling, injection drug use, and non-gay identification by men who have sex with men. Associations with high-risk sexual behaviors and condom use. Sex. Transm. Dis. 1998, 25:353-360.
122. Santibanez S.S., Garfein R.S., Swartzendruber A., et al. Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United States. J. Urban Health 2006, 83:86-100.
123. Sarang A., Stuikyte A., Bykoe R. Implementation of harm reduction in Central and Eastern Europe and Central Asia. Intl J. Drug Policy 2007, 18:129-135.
124. Schoenbaum G.M., Martin R.J., Roane D.S. Relationships between sustained sucrose-feeding and opioid tolerance and withdrawal. Pharmacol. Biochem. Behav. 1989, 34:911-914.
125. Schroeder J.R. Illicit drug use in one's social network and in one's neighborhood predicts individual heroin and cocaine use. Ann. Epidemiol. 2001, 11:389-394.
126. Sharan Society for Helping the Urban Poor (1997). Beyond Appearances. A monthly newsletter for the benefit of drug users and ex-drug users, August-September.
127. Sherman S.G. Correlates of initiation of injection drug use among young drug users in Baltimore, Maryland: the need for early intervention. J. Psychoactive Drugs 2005, 37:437-443.
128. Sherman S.G., Purchase D. Point Defiance: a case study of the United States' first public needle exchange in Tacoma, Washington. Intl J. Drug Policy 2001, 12:45-57.
129. Shin S.H., Lundgren L., Chassler D. Examining drug treatment entry patterns among young injection drug users. Am. J. Drug Alcohol Abuse 2007, 33:217-225.
130. Solomon L., Stein M., Flynn C., et al. Health services use by urban women with or at risk for HIV-1 infection, the HIV Epidemiology Research Study (HERS). J. Acquir. Immune Defic. Syndr. 1998, 17:253-261.
131. Stancliff S., Salomon N., Perlman D.C., Russell P.C. Provision of influenza and pneumococcal vaccines to injection drug users at a syringe exchange. J. Subst. Abuse. Treat. 2000, 18:263-265.
132. Strathdee S.A. Rise in needle sharing among injection drug users in Pakistan during the Afghanistan war. Drug Alcohol Depend. 2003, 71:17-24.
133. Strathdee S.A., Patrick D.M., Currie S.L., et al. Needle exchange is not enough, lessons from the Vancouver injecting drug use study. AIDS 1997, 11:F59-F65.
134. Strathdee S.A., Zafar T., Brahmbhatt H., et al. Rise in needle sharing among injection drug users in Pakistan during the Afghanistan war. Drug Alcohol Depend. 2003, 71:17-24.
135. Strathdee S.A., Ricketts E.P., Huettner S. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: results from a community-based behavioral intervention trial. Drug Alcohol Depend. 2006, 83:225-232.
136. Sullivan L.E., Fiellin D.A. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV patients with opioid dependence. HIV/AIDS, September 2005, 891-896.
137. Sullivan L.E., Metzger D.S., Fudala P.J., et al. Decreasing international HIV transmission, the role of expanding access to opioid agonist therapies for injection drug users. Addiction 2005, 100:150-158.
138. Takahashi L.M. Stigmatization, HIV/AIDS, and communities of color: exploring response to human service facilities. Health Place 1997, 3:187-199.
139. UNAIDS (1997). Report on the Global HIV/AIDS Epidemic, 1997. Geneva: United Nations Programme on HIV/AIDS.
140. UNAIDS (2002). Report on the Global HIV/AIDS Epidemic, 2002. Geneva: United Nations Programme on HIV/AIDS.
141. UNAIDS (2003). Health Canada: The Open Society Institute & The Canadian International Development Agency. The Warsaw Declaration: A Framework for Effective Action on HIV/AIDS and Injecting Drug Use. Second International Policy Dialogue on HIV/AIDS, Warsaw (Poland), November 12-14.
142. UNAIDS (2004). National Surveillance Report from China, Indonesia, and Vietnam. In: AIDS in Asia, Face the Facts, 2004 MAP Report, Figure 1. Geneva: United Nations Programme on HIV/AIDS.
143. Van Ameijden E.J., Van den Hoek J.A.R., Van Haastrecht H.J.A., Coutinho R.A. The harm reduction approach and risk factors for human immunodeficiency virus (HIV) seroconversion in injecting drug users, Amsterdam. Am. J. Epidemiol. 1992, 136:236-243.
144. Vlahov D., Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep. 1998, 113(Suppl. 1):75-80.
145. Vlahov D., Fuller C.M., Ompad D.C., et al. Updating the infection risk reduction hierarchy, preventing transition into injection. J. Urban Health 2004, 81:14-19.
146. Walters J.K., Estilo M.J., Clark G.L., Lorvick J.K. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. J. Am. Med. Assoc. 1994, 271:115-120.
147. Ward J.R., Mattick R., Hall W. The effectiveness of methadone maintenance treatment, an overview. Drug Alcohol Rev. 1994, 13:327-336.
148. Weinhardt L.S., Carey M.P., Johnson B.T., Bickham N.L. Effects of HIV counseling and testing on sexual risk behavior, a meta-analytic review of published research, 1985-1997. Am, J. Public Health 1999, 89:1397-1405.
149. White House Press Release (2003). President Delivers State of the Union. Available at (accessed 12-28-06). http://www.whitehouse.gov/news/releases/2003/01/20030128-19.html.
150. Williams C.T., Latkin C.A. Neighborhood socioeconomic status, personal network attributes, and use of heroin and cocaine. Am. J. Prev. Med. 2007, 32(Suppl.):S203-S210.
151. Williams D.R., Collins C. Racial residential segregation, a fundamental cause of racial disparities in health. Public Health Rep. 2001, 116:404-416.
152. Wolitski R.J., MacGowan R.J., Higgins D.L., Jorgensen C.M. The effects of HIV counseling and testing on risk-related practices and help-seeking behavior. AIDS Educ. Prev. 1997, 9:52-67.
153. World Health Organization (1997). STD/HIV/AIDS Surveillance Report, Special Edition. Manila: WHO Regional Office for the Western Pacific, Issue No. 10.
154. Wyatt G.E., Carmona J.V., Loeb T.B., Williams J.K. HIV-positive black women with histories of childhood sexual abuse, patterns of substance use and barriers to health care. J. Health Care Poor Underserved 2005, 16(Suppl. B):9-23.
155. Young R.M., Friedman S.R., Case P. Exploring an HIV paradox, an ethnography of sexual minority women injectors. J. Lesbian Studies 2005, 9:103-116.
156. Zule W.A. Risk and reciprocity, HIV and the injection drug user. J. Psychoactive Drugs 1992, 24:243-249.